UC Davis' Scott Fishman Pursues Global Center for Advancing Pain Relief
November 30, 2016
Hear Dr. Scott Fishman provide an overview of the pain epidemic in the United States, its causes, and the strength of UC Davis in filling this missing link.
Hear Dr. Scott Fishman provide an overview of the pain epidemic in the United States, its causes, and the strength of UC Davis in filling this missing link.
The CDC and FDA have both recently been expressing concerns about opioid abuse and potential overprescription.
Expanesthetics' Editors Note: Without new pain relievers that address the underlying issues, there are limited options to address the problems associated with opioids, including addiction.
There have been a number of transactions in the clinical development stage analgesia market, including Biogen's acquisition of Convergence's NaV1.7 antagonist program for $200M upfront and Novartis' acquisition of Spinifex's analgesic program that targets the angiotensin II type 2 receptor.
Spinnifex Pharmaceuticals has seen successful results in a Phase II trial for their novel angiotensin II type 2 receptor antagonist for the treatment of chronic pain published in the Lancet, and have recently agreed to be sold to Novartis International AG for $200M upfront payment plus undisclosed clinical development and regulatory milestone payments.
According to the American Acadamy of Emergency Medicine, alternative methods of analgesia to opioids are long overdue. Experts agree that reliance on opioids as a primary analgesic is a detriment to patient care, as they are unsafe and expensive.